The European Commission has granted conditional marketing authorization (Aic) for idecabtagene vicleucel (Ide-cel), the first T-cell based immunotherapy with chimeric antigen receptor (Car-T) directed against maturation antigen B cell (Bcma), for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and who have demonstrated disease progression to the last therapy. This was announced by Bristol Myers Squibb (Bms), noting that Ide-cel is the first and only approved Car-T therapy aimed at recognizing and binding to Bcma, a protein almost universally expressed on multiple myeloma cells, killing diseased cells.
Read Also
- Coronavirus Russia records record of deaths from covid in 24 hours Aug 26, 2021
- A critical analysis of the therapeutic protocol of the Pr Raoult Jul 1, 2020
- Debunked popular myths about breastfeeding Aug 2, 2020
- Consulcesi: ‘Specialization grants increase well but doctors flight remains’ Jul 19, 2021
- Editorial The pandemic taught colleges new ways Aug 22, 2021
- Named the best product to protect from hypertension Jul 12, 2020
- China will allow having three children per couple to alleviate the brake on the birth rate and the aging of the population May 31, 2021